- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00707148
Pertussis Vaccine in Healthy Pregnant Women
Safety and Immunogenicity of Tdap Vaccine in Healthy Pregnant Women, Safety in Their Neonates, and Effect of Maternal Immunization on Infant Immune Responses to DTaP Vaccine
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center - Duke Perinatal Clinic
-
-
Texas
-
Houston, Texas, United States, 77030-3411
- Baylor College of Medicine - Molecular Virology and Microbiology
-
-
Washington
-
Seattle, Washington, United States, 98101-1466
- Group Health Research Institute - Seattle
-
Seattle, Washington, United States, 98105-3901
- Seattle Children's Hospital - Infectious Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Pregnant subjects must meet all inclusion criteria in order to be eligible to participate in the study.
- 18 - 45 years of age
- In the 30th-32nd week of a pregnancy at low risk for complications as determined by the Obstetrical Risk Assessment Form [ORAF] and the following criteria:
All Pregnant Women:
- Second trimester or later ultrasound with no significant abnormalities.
Alpha fetal protein (AFP) testing, one of the following:
- Normal maternal serum AFP performed at 15-20 weeks' gestation (either as part of the quad screen or separately)
- Abnormal maternal serum AFP at 15-20 weeks' gestation followed by an amniocentesis demonstrating no chromosomal abnormalities AND either normal amniotic fluid AFP or normal amniotic fluid acetylcholinesterase (AChE) levels.
- If a serum AFP test is not performed, one of the following:
i. A level II ultrasound with no significant abnormalities ii. A normal amniotic fluid AFP test AND an amniocentesis demonstrating no chromosomal abnormalities must be documented.
Pregnant Women 40-45 years of age: no chromosomal abnormalities identified by diagnostic testing [chorionic villus sampling (CVS) or amniocentesis].
Pregnant Women 18-39 years of age: at least one of the following:
- Level II ultrasound with no significant abnormalities
- No chromosomal abnormalities identified by diagnostic testing (CVS or amniocentesis)
- Pregnancy estimated to be at low risk (< 1 in 270) for Down's syndrome (trisomy 21), trisomy 13 and trisomy 18 by appropriate first or second trimester screening test. Appropriate screening test includes any one of the following:
i. first trimester screening (nuchal translucency measurement, pregnancy-associated plasma protein A (PAPP-A), and beta- human chorionic gonadotropin (B-hCG) ii. first trimester screening and second trimester quad screen, with risk estimated using an integrated, sequential, or contingency approach iii. second trimester quad screen alone
- Intend to be available for follow-up visits and phone call access through 13 months following delivery
- Willing to have infant immunized with Pentacel vaccine at 2, 4, 6, and 12 months of age
- Willing to give written informed consent
Non-pregnant subjects must meet all inclusion criteria in order to be eligible to participate in the study.
- 18-39 years of age or 40-45 years of age
- Intend to be available for a follow-up visit and phone call access through 6 months following receipt of Adacel vaccine
- Willing to give written informed consent
- Must fulfill one of the following: (i) she is not able to bear children because she has been surgically sterilized (tubal ligation, bilateral oophorectomy or hysterectomy) for at least one year or is at least 1 year post-menopausal or (ii) she agrees to practice effective methods of contraception including, but not limited to, abstinence, monogamous relationship with vasectomized partner, barrier methods, birth control pills, patches or hormonal shots or hormonal implants, NuvaRing and IUDs (intrauterine devices), during the study period between enrollment and 30 days following receipt of the vaccine. (If subject is of childbearing potential, the method of birth control will be documented.)
- For a female subject of childbearing potential, must have a negative pregnancy test (urine or serum) within 24 hours prior to vaccination
Exclusion Criteria:
Pregnant subjects who meet any exclusion criteria at baseline will be excluded from the study.
- Serious underlying medical condition (e.g., immunosuppressive disease or therapy, human immunodeficiency virus (HIV) infection, collagen vascular disease, diabetes mellitus, chronic hypertension, moderate to severe asthma, lung/heart disease, liver/kidney disease, chronic or recurrent infections).
- Significant mental illness (e.g. schizophrenia, psychosis, major depression).
- Currently smoking or using illegal substances.
- History of a febrile illness (greater than or equal to 100.4 degrees Fahrenheit or 38 degrees Celsius) within the past 72 hours for antepartum injection or febrile illness (greater than or equal to 100.4 degrees Fahrenheit or 38 degrees Celsius) within 24 hours for postpartum injection.
- Previous severe reaction to any vaccine.
- Receipt of tetanus-diphtheria toxoid immunization within the past 2 years.
- Receipt of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap) immunization ever.
- Receipt of a vaccine (excluding influenza), blood product (excluding Rhogam) or experimental medicine within the 4 weeks prior to antepartum injection through 4 weeks following post-partum injection. However, measles-mumps-rubella vaccine is permitted post-partum.
- Receipt of or plans to receive influenza vaccine within the 2 weeks prior to or following antepartum injection.
- Deemed high risk for serious obstetrical complication as determined by the Obstetrical Risk Assessment Form.
- Anything in the opinion of the investigator that would prevent volunteers from completing the study or put the volunteer at risk.
Non-pregnant subjects who meet any exclusion criteria at baseline will be excluded from the study.
- Serious underlying medical condition (e.g., immunosuppressive disease or therapy, HIV infection, collagen vascular disease, diabetes mellitus, chronic hypertension, moderate to severe asthma, lung/heart disease, liver/kidney disease, chronic or recurrent infections).
- Significant mental illness (e.g. schizophrenia, psychosis, major depression).
- Currently smoking or using illegal substances.
- History of a febrile illness (greater than or equal to 100.4 degrees Fahrenheit or 38 degrees Celsius) within the past 24 hours.
- Previous severe reaction to any vaccine.
- Receipt of tetanus-diphtheria toxoid immunization within the past 2 years.
- Receipt of Tdap immunization ever.
- Receipt of or plans to receive an investigational or licensed vaccine (excluding influenza), blood product or experimental medicine within the 4 weeks prior to Adacel vaccination through 4 weeks following Adacel vaccination
- Receipt of or plans to receive influenza vaccine within the 2 weeks prior to or following Adacel vaccination.
- Intends to become pregnant during the study period between enrollment and 30 days following receipt of the vaccine.
- Anything in the opinion of the investigator that would prevent a volunteer from completing the study or put the volunteer at risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Group 2: Control
16 pregnant women to receive: antepartum: saline; postpartum; Tdap vaccine.
|
Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap).
Administered as a single 0.5 mL intramuscular injection into the deltoid.
|
EXPERIMENTAL: Group 1: Intervention
32 pregnant women to receive: antepartum: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) vaccine; postpartum: saline.
|
Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap).
Administered as a single 0.5 mL intramuscular injection into the deltoid.
|
ACTIVE_COMPARATOR: Group 3: Control
32 non-pregnant women to receive a single dose of Tdap vaccine.
|
Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap).
Administered as a single 0.5 mL intramuscular injection into the deltoid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of injection site and systemic reactions following injections.
Time Frame: Recorded 0 to 7 days after injection.
|
Recorded 0 to 7 days after injection.
|
Frequency of vaccine-associated adverse events (AEs).
Time Frame: 30 minutes post-injection, Day 0, 1-2, 7, 4 weeks post-injection, delivery, Day 1-2, 7, and 2 and 4 months post-delivery. Infant AEs: Delivery, 2, 4, 7, and 13 months. Non-pregnant: Day 0, 1-2, 7, 4 weeks and 6 months.
|
30 minutes post-injection, Day 0, 1-2, 7, 4 weeks post-injection, delivery, Day 1-2, 7, and 2 and 4 months post-delivery. Infant AEs: Delivery, 2, 4, 7, and 13 months. Non-pregnant: Day 0, 1-2, 7, 4 weeks and 6 months.
|
Frequency of vaccine-associated serious adverse events (SAEs).
Time Frame: Maternal SAEs through 4 months post delivery and infant SAEs from delivery to 13 months. Non-pregnant SAEs: Day 0 through to 6 months post-injection.
|
Maternal SAEs through 4 months post delivery and infant SAEs from delivery to 13 months. Non-pregnant SAEs: Day 0 through to 6 months post-injection.
|
Infant growth measurements (fronto-occipital circumference [FOC], length and weight).
Time Frame: At delivery and at 2, 7 and 13 months of age.
|
At delivery and at 2, 7 and 13 months of age.
|
Bayley III developmental screening of infants.
Time Frame: At age 13 months.
|
At age 13 months.
|
Incidence of pertussis infection captured by surveillance for adverse events (AEs) and serious adverse events (SAEs).
Time Frame: Duration of study, captured by surveillance for AEs and SAEs. Antepartum: Day 1-2 and 7; 4 weeks; delivery. Postpartum: Day 1-2 and 7; Month 2, 4,7, and 13.
|
Duration of study, captured by surveillance for AEs and SAEs. Antepartum: Day 1-2 and 7; 4 weeks; delivery. Postpartum: Day 1-2 and 7; Month 2, 4,7, and 13.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Concentrations of immunoglobulin G (IgG) for pertussis toxin (PT), pertactin (PRN), fimbrial proteins (FIM), filamentous hemagglutinin (FHA), tetanus toxoid (TT), and diphtheria toxoid (DT).
Time Frame: Mother: blood samples collected before and 4 weeks after antepartum injection, at hospital admission for delivery and at the 2 month post delivery visit. Infant: collected at delivery (cord), 2, 7 and 13 months of age.
|
Mother: blood samples collected before and 4 weeks after antepartum injection, at hospital admission for delivery and at the 2 month post delivery visit. Infant: collected at delivery (cord), 2, 7 and 13 months of age.
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Bordetella Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Clostridium Infections
- Corynebacterium Infections
- Whooping Cough
- Tetanus
- Diphtheria
Other Study ID Numbers
- 05-0048
- HHSN272200800002C
- H-19633
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pertussis
-
National Institute of Allergy and Infectious Diseases...CompletedPertussis | Pertussis ImmunisationUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis (Whooping Cough)France
-
Institut PasteurHopital Universitaire Robert-Debre; Hospices Civils de Lyon; Centre Hospitalier... and other collaboratorsNot yet recruitingBordetella Pertussis, Whooping CoughFrance
-
ILiAD BiotechnologiesActive, not recruitingBordetella Pertussis, Whooping CoughUnited Kingdom, Australia, Costa Rica
-
University of TurkuGlaxoSmithKline; Sanofi Pasteur, a Sanofi CompanyCompleted
-
Institut PasteurAgence de Médecine Préventive, France; Institut Pasteur de Madagascar; Institut...CompletedBordetella Pertussis, Whooping CoughCambodia, Madagascar, Togo
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
GlaxoSmithKlineCompletedPertussis | Pertussis VaccinesHungary
-
University of SouthamptonRecruitingPertussis/Whooping CoughUnited Kingdom
-
Association Clinique Thérapeutique Infantile du...Sanofi; GlaxoSmithKline; Merck Sharp & Dohme LLCRecruitingChildren, Only | Ambulatory | Pertussis/Whooping CoughFrance
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States